Novel JAK inhibitor acts locally in the gut for ulcerative colitis treatment

A gut-selective Janis kinase inhibitor called TD-1473 showed a trend toward reduced ulcerative colitis disease activity in a translational medicine program.William J. Sandborn, MD, from the division of gastroenterology at the University of California, San Diego, told Healio Gastroenterology and Liver Disease that unlike other JAK inhibitors such as Xeljanz (tofacitinib, Pfizer), TD-1473 (Theravance) does not work systemically, but rather only in the location it is delivered, in this case, the gut, allowing it to be effective by administering higher doses without increasing adverse events.“It’sRead More

Share on facebook
Share on twitter
Share on linkedin